Forecasting of emerging therapeutic monoclonal antibodies patents based on a decision model

Pereira, Cristiano G.; Lavoie, João Ricardo; Garces, Edwin; Basso, Fernanda Gisele; Dabić, Marina; Porto, Geciâne Silveira; Daim, Tuğrul U.

doi:10.1016/j.techfore.2018.11.002

Cited by 32 publications

(7 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They proposed a process to map a technological trajectory of a set of patents, understand knowledge flow, most relevant technology on the route and point out the emerging technologies. Thus, from the construction of patent citation networks, it is possible to identify the temporal evolution of a technology, through the various players who have developed technological contributions until the latest technologies, also called emerging technologies (Pereira and Porto, 2018;Pereira et al, 2019).…”

Section: Review Of Methods For Technological Forecasting Based On Patent Analysismentioning

confidence: 99%

“…However, it is observed that trends analysis on GVP based on knowledge flow are not commonly used, especially when they come from patent data, thus missing an opportunity to aggregate value in the understanding of future trends. This must be considered because relevant technological information is described in granted patents that cover several knowledge areas and are reliable sources of technological innovations (Blackman, 1995;Ardito et al 2018;Pereira et al, 2019;Eilers et al, 2019).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Emerging green technologies for vehicle propulsion systems

Paulo

Nunes

Porto

2020

Technological Forecasting and Social Change

View full text Add to dashboard Cite

Breno Nunes 2 Geciane Porto 3 IntroductionThe climate change caused by greenhouse gases emissions in the atmosphere has been widely discussed for years. The transport area is one of the largest contributors for this scenario accounting for 23% of total CO2 emissions. This is because 95% of the energy used in transport comes from fossil fuels (Sims et al., 2014). Globally, transport is likely to continue being a big source of pollution, particularly urban air pollution. While the mobility by car is forecast to only grow 32% by 2050 in OECD countries; it will raise by a staggering 185% in non-OECD countries (ITF, 2017). If initiatives are not taken to find and use alternative and non-polluting energy sources at a reasonable cost, this demand may further jeopardize the planet's environmental conditions (IPCC, 2014a, Creutzig et al., 2015. Numerous treaties have already been proposed at global level to establish policies that foster clean technology initiatives and mitigate environmental impacts. Paris Agreement is the most recent one (UNFCCC, 2015). New legislation is coming in place to ban the sales of new petrol and diesel vehicles in countries like Denmark, Germany, France, and United Kingdom by 2040. Burch and Gilchrist (2018) also point out the list of actions from dozens of other countries to phase-out the production of combustion vehicles as well as the incentive to adopt EVs (electric vehicles). Despite the rapid evolution in the development of EVs, technological learning for the transition to a low carbon transport system still has challenges that depend on innovations in energy storage technologies such as batteries as well as at infrastructural and policy level, i.e. better plan for electric grid infrastructure (Kittner et al., 2020).Clean energy generation through renewable sources, among them solar, wind, water or biomass is also a key step to reduce greenhouse gas emissions. Hydrogen has been pointed out as an alternative (Johnston et al. 2005) however its commercial application (e.g. full cells) are still growing slowly. In particular, solar and wind power have been subject of increasing

show abstract

Section: Review Of Methods For Technological Forecasting Based On Patent Analysismentioning

confidence: 99%

mentioning

confidence: 99%

Emerging green technologies for vehicle propulsion systems

Paulo

Nunes

Porto

2020

Technological Forecasting and Social Change

View full text Add to dashboard Cite

show abstract

“…In fact studying such patents could provide an early indication of approvals to come. 37 This might be specifically true in the sphere of single domain antibodies. There is just one such approved therapeutic on the market 34 and 10 in clinical trials 35 (in 2019).…”

Section: Discussionmentioning

confidence: 99%

Data mining patented antibody sequences

Krawczyk

Buchanan

Marcatili

2021

mAbs

View full text Add to dashboard Cite

The patent literature should reflect the past 30 years of engineering efforts directed toward developing monoclonal antibody therapeutics. Such information is potentially valuable for rational antibody design. Patents, however, are designed not to convey scientific knowledge, but to provide legal protection. It is not obvious whether antibody information from patent documents, such as antibody sequences, is useful in conveying engineering know-how, rather than as a legal reference only. To assess the utility of patent data for therapeutic antibody engineering, we quantified the amount of antibody sequences in patents destined for medicinal purposes and how well they reflect the primary sequences of therapeutic antibodies in clinical use. We identified 16,526 patent families covering major jurisdictions (e.g., US Patent and Trademark Office (USPTO) and World Intellectual Property Organization) that contained antibody sequences. These families held 245,109 unique antibody chains (135,397 heavy chains and 109,712 light chains) that we compiled in our Patented Antibody Database (PAD, http://naturalantibody.com/pad). We find that antibodies make up a non-trivial proportion of all patent amino acid sequence depositions (e.g., 11% of USPTO Full Text database). Our analysis of the 16,526 families demonstrates that the volume of patent documents with antibody sequences is growing, with the majority of documents classified as containing antibodies for medicinal purposes. We further studied the 245,109 antibody chains from patent literature to reveal that they very well reflect the primary sequences of antibody therapeutics in clinical use. This suggests that the patent literature could serve as a reference for previous engineering efforts to improve rational antibody design.

show abstract

“…The already large amount of antibodies from patent documents will most likely keep rising, as we demonstrated by the growth in the number of such documents in the recent years. In fact studying such patents could provide an early indication of approvals to come 37 . This might be specifically true in the sphere of single domain antibodies.…”

Section: Discussionmentioning

confidence: 99%

Data mining patented antibody sequences

Krawczyk¹,

Buchanan

Marcatili

2020

Preprint

View full text Add to dashboard Cite

Patent literature should be a reflection of thirty years of engineering efforts in developing monoclonal antibody therapeutics. Such information is potentially valuable for rational antibody design. Patents however are not designed to convey scientific knowledge, but rather legal protection. It is unclear whether antibody information from patent documents, such as antibody sequences could be useful for the therapeutic antibody sphere in conveying engineering know-how rather than act as legal reference only. To assess the utility of patent data for therapeutic antibody engineering, we quantified the amount of antibody sequences in patents destined for medicinal purposes and how well they reflect the primary sequences of therapeutic antibodies in clinical use. We identified 16,526 patent families from major jurisdictions (e.g. USPTO and WIPO) that contained antibody sequences. These families held 245,109 unique antibody chains (135,397 heavy chains and 109,712 light chains) that we compiled in our Patented Antibody Database (PAD, http://naturalantibody.com/pad). We find that antibodies make up a non-trivial proportion of all patent amino acid sequence depositions (e.g. 10.95% of USPTO Full Text database). Our analysis of the 16,526 families demonstrates that the volume of patent documents with antibody sequences is growing with the majority of documents classified as containing antibodies for medicinal purposes. We further studied the 245,109 antibody chains from patent literature to reveal that they very well reflect the primary sequences of antibody therapeutics in clinical use. This suggests that patent literature could serve as a reference of previous engineering efforts to improve rational antibody design.

show abstract

Forecasting of emerging therapeutic monoclonal antibodies patents based on a decision model

Cited by 32 publications

References 59 publications

Emerging green technologies for vehicle propulsion systems

Emerging green technologies for vehicle propulsion systems

Data mining patented antibody sequences

Data mining patented antibody sequences

Contact Info

Product

Resources

About